Precision diagnosis and treatment technologies unravel the mysteries of antibody-mediated rejection in kidney transplantation: breakthroughs and future directions
10.3760/cma.j.cn421203-20240910-00190
- VernacularTitle:精准诊疗技术拨开肾移植抗体介导排斥反应的迷雾：突破与未来
- Author:
Changxi WANG
1
;
Huanxi ZHANG
Author Information
1. 中山大学附属第一医院器官移植中心，广州 510080
- Keywords:
Kidney Transplantation;
Antibody-mediated rejection;
Precision medicine;
Treatment
- From:
Chinese Journal of Organ Transplantation
2024;45(9):610-613
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-mediated rejection (AMR) remains a leading cause of graft failure in kidney transplantation. The development of AMR is driven by complex immune mechanisms, including donor-specific antibodies (DSA), antibody-mediated cytotoxicity, and complement system activation, which have collectively contributed to the current suboptimal treatment outcomes. Emerging non-invasive monitoring tools, such as donor-derived cell-free DNA and non-HLA antibodies, offer novel approaches for the early detection of AMR. The application of multi-omics technologies has unveiled the intricate immune mechanisms involved in AMR, laying a solid foundation for more precise classification and personalized treatment strategies. Moreover, new therapeutic agents, such as CD38 monoclonal antibodies, IL-6 inhibitors, and complement inhibitors, which target specific immune pathways involved in AMR pathogenesis, have shown promising clinical results. With the rapid advancement of precision diagnostic and therapeutic techniques, there is great potential for significant breakthroughs in the diagnosis and treatment of AMR in kidney transplantation.
